Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a)

Ayelet Gonen1, Xiaohong Yang2, Calvin Yeang2, Elena Alekseeva1, Marlys Koschinsky3, Joseph L. Witztum1, Michael Boffa2, and Sotirios Tsimikas2,*

1Division of Endocrinology and Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA, USA, 2Vascular Medicine Program, Sulpizio Cardiovascular Center, Division of Cardiology,1 University of California San Diego, La Jolla, CA, USA, 3Robarts Research Institute, Schulich School of Medicine and Dentistry, University of Western Ontario, London, ON, Canada, 4Department of Biochemistry, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada

Abstract Lipoprotein (a) [Lp(a)] is a risk factor for CVD and a target of therapy, but Lp(a) measurements are not globally standardized. Commercially available assays generally use polyclonal antibodies that detect multiple sites within the kringle (K)IV repeat region of Lp(a) and may lead to inaccurate assessments of plasma levels. With increasing awareness of Lp(a) as a cardiovascular risk factor and the active clinical development of new potential therapeutic approaches, the broad availability of reagents capable of providing isoform independence of Lp(a) measurements is paramount. To address this issue, we generated a murine monoclonal antibody that binds to only one site on apo(a). A BALB/C mouse was immunized with a truncated version of apo(a) that contained eight total KIV repeats, including only one copy of KIV2. We generated hybridomas, screened them, and successfully produced a KIV2-independent monoclonal antibody, named LPA-KIV9. Using a variety of truncated apo(a) constructs to map its binding site, we found that LPA-KIV9 binds to KIV9 without binding to plasminogen. Fine peptide mapping revealed that LPA-KIV9 bound to the sequence 4076LETPTVV4082 on KIV9.

In conclusion, the generation of monoclonal antibody LPA-KIV9 may be a useful reagent in basic research studies and in the clinical application of Lp(a) measurements.

Supplementary key words lipoprotein (a) • monoclonal antibody • isoform • kringle • cardiovascular disease • aortic stenosis • metabolism, therapy • lipoprotein (a)-kringle IV9

Lipoprotein (a) [Lp(a)] is composed of apo(a) covalently bound to apoB-100 (1). Apo(a) consists of 10 unique kringle (K)IV repeats that are present in one copy, except for KIV2, which is present in a variable number of identical copies at the protein level (1 to >40). It also contains one copy of KV and an inactive protease-like domain. The apo(a) protein displays broad size heterogeneity due to a variable number of KIV2 repeats among individuals and populations. Plasma Lp(a) levels are genetically determined by the production and secretion rate of apo(a) by hepatocytes, with isoforms containing a small number of KIV2 repeats being secreted more efficiently, leading to an inverse association of KIV2 repeat number and plasma Lp(a) levels (2).

Elevated Lp(a) is highly prevalent, with an estimated 20% of the population having levels >50 mg/dl (>125 nmol/l), the threshold above which risk accrues in statin-treated patients (3, 4). Lp(a) is also a target of therapy, with recent studies showing that antisense oligonucleotides may lower Lp(a) by over 80% (5–7), and a phase 3 clinical trial that is now underway (https://clinicaltrials.gov/ct2/show/NCT04023552). Multiple national and international societies have suggested that Lp(a) be measured in individuals at moderate to high risk for CVD to enhance risk prediction or for considerations as a risk enhancer (8–14).

Many commercially available assays exist to measure plasma Lp(a), but assay reagents and methodologies vary among manufacturers and have not been globally standardized. It is anticipated that the testing of Lp(a) values will expand with recent European guidelines that have recommended that every adult person have Lp(a) measured at least once in their lifetime (14), as well as by the development of new therapies capable of substantially lowering Lp(a) (5). To date, only one isoform-independent antibody binding to KIV9 on apo(a) has been described and well-characterized, but its peptide epitope has not been reported. This antibody has been used to develop an ELISA method, and the ELISA has been used to assign a target value to the WHO/IFCC reference material, and it is also used as a comparison method to validate commercial assays. However, while the method has been used in a variety of clinical studies, it is not at present commercially available (15). In this study, we describe the generation and characterization of a new murine monoclonal antibody that binds to a defined peptide sequence present only once.

This article contains supplemental data.

*For correspondence: Sotirios Tsimikas, tsimikas@ucsd.edu.
in KIV9 that can be used in both basic and clinical aspects of Lp(a) research and Lp(a) measurements.

**METHODS**

**Generation of immunogens and antigens**

To generate immunogens, we used two approaches. First, we generated several truncated apo(a) proteins for use as immunogens. One construct spanned the entire KIV10-KV sequence, and its generation and purification are described in the supplemental material. A second large apo(a) construct, designated 8K-IV, contained one copy of KIV9, one copy of KIV7, and KIV8, and individual kringle, KIV3 to KIV9, KIV10, and the protease-like domain, as previously described (16). Second, as a different strategy, we generated several unique short peptides derived from apo(a) but not present on plasminogen, which were conjugated to keyhole limpet hemocyanin for immunization. These included peptide GDGRSYRGISSTVT present in one copy on KIV5 and peptide MNPRKLFDYC present in one copy on KV.

Screening antigens included Lp(a) purified from a single donor as previously described (17), human plasminogen (R&D, Minneapolis, MN), and a variety of recombinant apo(a) constructs, including two KIV2 constructs containing either three or five copies, various constructs spanning consecutively from KIV6 to the protease domain (KIV6, KIV7, KIV8, KIV9, KIV10, KIV11, respectively), a 17 kringle human construct with eight KIV2 repeats, a 17 kringle construct without the protease domain (17KΔP), and a 17 kringle construct without KV (17KΔKV) (18, 19).

The disulfide bond between apoB-100 and apo(a) is composed of cysteine 4236 of apoB-100 and cysteine 4057 of apo(a). Murine monoclonal antibody MB47, specific for human apoB-100 of cysteine 4236 of apoB-100 and cysteine 4057 on apo(a) (20). A 17 kringle construct without the protease domain (17KΔP), and a 17 kringle construct without KV (17KΔKV) (18, 19).

Immunization of mice and generation and purification of monoclonal antibodies

All animal experiments were conducted according to protocols approved by the Institutional Animal Care and Use Committee of the University of California San Diego. BALB/C mice were immunized intraperitoneally with keyhole limpet hemocyanin-conjugated peptides GDGRSYRGISSTVT and MNPRKLFDYC, as well as apo(a) construct KIV10-KV, but these immunogens produced no specific antibodies or the resulting antibodies bound to KIV2 and/or plasminogen, therefore no further work was performed with them and the results are not presented.

A BALB/C mouse was immunized with a similar protocol as previously described (25), with a primary boost of 125 μg of the 8K-IV apo(a) construct, followed at 2 week intervals with three intraperitoneal boosts with 75 μg. A final antigen boost of 25 μg of 8K-IV in PBS was administered intravenously 2 weeks after the third boost. Three days later, the mouse was euthanized, splenocytes were collected and fused with myeloma cells (p3X63Ag8.653) using a ClonCell™-HY hybridoma kit (StemCell Technologies, Cambridge, MA), and the fused cells were resuspended in semi-solid HAT hybridoma selection medium. After 10–14 days, visible colonies were transferred to ClonCell™-HY growth medium (DMEM, preselected serum, HT, gentamycin, and supplements).

To select colonies expressing antibodies specific to Lp(a) without binding to plasminogen or KIV9, conditioned media from the hybridoma cells were screened by ELISA as described below. To ensure monoclonality, selected clones that bound Lp(a) but not KIV9 or plasminogen were subcloned twice by limiting dilution in semi-solid gel, without HAT, and retested by ELISA. The resulting heavy and light chains of two colonies were sequenced (Genscript, Piscataway, NJ) and were found to be identical in sequence. The cells were expanded by BioXCell (West Lebanon, NH) in tissue culture in a stirred tank fermentation with Hybridoma-SFM medium supplemented with 1% Fetal Clone 3 (Life Technologies, Carlsbad, CA) and antibody purified with chromatography over Protein A/G resin. Determination of antibody isotype was carried out using the ISOStrip mouse monoclonal antibody isotyping kit (Roche Diagnostics, Vilvoorde, Belgium). This monoclonal antibody was designated as “LPA-KIV9”.

**ELISA with direct antigen plating to assess binding of hybridoma-generated antibodies**

Titrations of antibodies present in immunized mouse plasma, screening of hybridoma-conditioned media, and testing the purified monoclonal antibody were performed by chemiluminescent ELISA as previously described (25). In brief, 96-well microtiter plates (Brand, Germany) were coated directly with Lp(a), apo(a) KIV2 construct, or plasminogen at 5 μg/ml in PBS overnight at 4°C. Nonspecific sites were blocked with 1% BSA (Gemini Bioproducts, USA, CA) in TBS (1% BSA-TBS) and incubated for 30 min at room temperature. Subsequently, serial dilutions of mouse plasma (1:50 to 1:400) in 1% BSA-TBS or hybridoma-conditioned media (undiluted) were added and incubated for 60 min at room temperature. Bound IgG antibodies were detected using an anti-mouse IgG alkaline phosphatase conjugate (Sigma-Aldrich, St. Louis, MO) and Lumi-Phos 530 substrate (Lumigen, Southfield, MI) on a luminescence plate reader (BioTek, Winooski, VT). Antibody binding was expressed as relative light units detected over 100 ms (RLU/100 ms).

**Immunoblot analyses**

An array of apo(a) constructs (18, 19, 26) was subjected to gel electrophoresis and immunoblot analysis with LPA-KIV9. Briefly, samples (250 ng/well) were loaded in reducing loading buffer and run on a 4–12% Bis-Tris gel (Life Technologies). Gels were transferred to a PVDF membrane (Life Technologies), and the membranes were blocked with 5% nonfat dry milk in TBS and TWEEN (TBST) for 1 h before incubation with primary antibodies (1 μg/ml in 1% BSA-TBST) overnight at 4°C, followed by incubation with secondary antibodies conjugated with horseradish peroxidase (Cell Signaling Technology, Beverly, MA) for 1 h at room temperature and by detection with KPL-TMB membrane peroxidase substrate (SeraCare, Milford, MA). A dot-blot was also performed with antibodies in PBS (25 ng/dot) loaded directly on the membrane. Blocking and immunoblotting were done as described above and detected by a Super Signal West Dura substrate (Thermo Fisher Scientific, Waltham, MA) and an OptiChem HR imaging system (UVP, Upland, CA).

**CDR sequences of LPA-KIV9**

TRIzo® reagent (Ambion, #15596-026); PrimeScript™ 1st Strand cDNA synthesis kit (Takara, #6110A). Total RNA was isolated from the hybridoma cells following the technical manual of TRIzo® reagent. Total RNA was then reverse-transcribed into cDNA using either isotype-specific antisense primers or universal primers following the technical manual of PrimeScript™ 1st Strand cDNA synthesis kit. Antibody fragments of heavy chain and
Monoclonal antibody to Lp(a)

light chain were amplified according to the standard operating procedure of rapid amplification of cDNA ends of GenScript. Amplified antibody fragments were cloned into a standard cloning vector separately. Colony PCR was performed to screen for clones with inserts of correct sizes. The consensus sequence was provided.

Peptide library array to determine peptide antigen of LPA-KIV9

A peptide library array spanning KIV9, consisting of 100 overlapping 15 amino acid peptides differing by only one amino acid residue was synthesized on cellulose membranes (JPT, Germany). LPA-KIV9 binding was detected using anti-mouse IgG antibody conjugated with horseradish peroxidase and SuperSignal West Dura HRP chemiluminescent substrate (Thermo Scientific). Swiss-model structure online analysis software was used to simulate the epitope location on a three-dimensional structural model of KIV9, KIV10 (27). The alignment template SMTL ID was 4dur.2.A, plasminogen, with 57.55% sequence identity. The alignment modeling sequence of apo(a) was from A3866 to V4190.

Statistics

Descriptive statistical analysis and correlation analysis were performed with Spearman’s rho test using SPSS version 26.

RESULTS

Generation and characterization of monoclonal antibodies

Following the immunization protocol using the 8K-IV apo(a) construct, mouse plasma was screened for the generation of IgG monoclonal antibodies binding Lp(a). Plasma contained strong binding to the 8K-IV apo(a) construct and Lp(a), with only background levels of binding to the K(IV2)3 construct (Fig. 1A). Hybridomas were then generated, and 576 colonies were collected, expanded, and screened by ELISA for production of IgG antibodies against Lp(a), resulting in 88 positive colonies that were expanded and restested. Two colonies were selected for their robust IgG binding to Lp(a) but not K(IV2)3 (Fig. 1B). Both colonies were subjected to two cycles of limiting dilution to ensure monoclonality. All daughter clones were positive for binding to Lp(a) but not to K(IV2)3 or plasminogen (Fig. 1C). On further analysis, the two clones were found to have identical CDR3 sequences in their heavy and light chains and thus were derived from the same clone. Colony #1 was retested five times and designated LPA-KIV9. D: Purified LPA-KIV9 binding to Lp(a) (5 μg/ml) was tested by ELISA. The graph shows the mean of two to four technical replicates (mean ± SD).
ELISA of the purified LPA-KIV9 showed a dose-dependent specific reactivity with Lp(a), with no cross-reactivity with K(IV2)3 or plasminogen (Fig. 1D).

Determination of the binding domain of LPA-KIV9 on apo(a)

To determine the site on apo(a) to which LPA-KIV9 bound, we tested its binding to an array of apo(a))-recombinant constructs by dot-blot (Fig. 3A) and Western blot (Fig. 3B). By dot-blot, LPA-KIV9 reacted with constructs containing various numbers of kringle segments, including KIV6-P, KIV7-P, KIV8-P, and KIV9-P containing sequences from KIV 6, KIV 7, KIV 8, and KIV 9 to end of protease domain, respectively. It also recognized the 17 kringle full-length human construct, the 17K V construct missing KV, and the 17K P construct missing the protease-like domain (Fig. 3A). However, LPA-KIV9 did not react with KIV10-P and K(IV2)5, i.e., the only constructs not containing KIV9, consistent with the epitope being present on KIV9. This specific binding pattern was duplicated with Western blotting showing that the presence of KIV9 was required for LPA-KIV9 immunoreactivity (Fig. 3B).

Determination of the specific peptide sequence on the epitope recognized by LPA-KIV9

A peptide library spanning KIV9 consisting of 100 overlapping peptides, each 15 amino acids in length, was designed (Fig. 4A). Antibody LPA-KIV9 bound to nine overlapping peptide fragments on KIV9 (Fig. 4B), which comprised the 7-amino acid epitope LETPTVV at positions 4076–4082 (Fig. 4C). This epitope is 19 amino acids downstream of cysteine 4057 on apo(a) (shown in orange in Fig. 4D) that creates the disulfide bond with cysteine 4236 of apoB-100 (20). The three-dimensional structure of the epitope on apo(a) was predicted by a Swiss-model server, showing that it is a loop surface epitope toward the C-terminal end of KIV9 (shown in green in Fig. 4D) and three amino acids away from KIV10.
DISCUSSION

This study describes the generation and characterization of a murine monoclonal antibody, LPA-KIV9, that detects a unique 7-amino acid epitope on KIV9 of apo(a) present only in one copy. The generation of this new monoclonal antibody will hopefully allow for development of an isoform-independent assay for the measurement of plasma Lp(a) levels. By virtue of binding only one site on apo(a), it may address some of the limitations of clinical Lp(a) assays that utilize polyclonal antibodies binding multiple sites on apo(a) that can lead to either overestimation or underestimation of Lp(a) levels.

In 2018, an National Heart, Lung, and Blood Institute Working Group recommended the development of a globally standardized measurement of Lp(a) applicable to commercial laboratories (3) and that reporting total Lp(a) mass in milligrams per deciliter be discontinued and values reported in nanomoles per liter traceable to a common reference system. Furthermore, harmonization of results obtained by the different methods should be performed after an accuracy-based common calibration is performed.

A recent study evaluating Lp(a) levels by six commercially available methods concluded that current commercial immunological assays are differently calibrated and their biases differed significantly across the clinically relevant concentration range in a nonlinear manner not entirely dependent on apo(a) phenotypes (28). Most commercially available assays use polyclonal antibodies, which are a mixture of antibodies that may bind throughout the apo(a) protein, including the potential for binding multiple times within the KIV2 region. Furthermore, assay calibrators are usually derived from pooled plasma of multiple donors but generally cannot represent all known apo(a) isoforms present in the samples being measured. Relative to the calibrators, polyclonal antibodies bind more frequently to larger apo(a) isoforms, which are found in subjects with low plasma Lp(a) and thus tend to overestimate these values. In contrast, such antibodies bind less frequently to small isoforms, which are found in Lp(a) in subjects with high plasma Lp(a) and thus tend to underestimate values (24, 29).

The difficulty in generating monoclonal antibodies unique to Lp(a) outside the KIV2 region that also do not cross-react with plasminogen, which has substantial homology to apo(a) (30), suggests that only a limited number of antigenic sites are available to generate such antibodies. Consistent with this, in the current study, despite an intensive and wide-ranging approach to develop novel antibodies with multiple immunogens, only two clones were identified as being isoform independent and only binding one site, and both were identical in sequence. Three-dimensional mapping suggests that the epitope LETPTVV of LPA-KIV9 protrudes outward from the other kringles and may be immunologically more accessible.

For clinical applications, future efforts will be concentrated on developing high-throughput assay methods to measure Lp(a). Furthermore, validation of isoform independence in samples with known isoform size will be required once a clinically optimized assay method is developed.

In conclusion, the murine monoclonal antibody, LPA-KIV9, may be useful in developing optimized methods to measure Lp(a) in both research and clinical settings.

Data availability

Data that support the plots within this publication and other findings of this study are available from the corresponding author upon request.

Acknowledgments

The authors thank Phuong Miu for technical assistance and Xuchu Que for assistance in aligning the heavy and light chain CDR regions of LPA-KIV9.

Author ORCIDs

Sotirios Tsimikas https://orcid.org/0000-0001-9834-9494

Fig. 3. Identification of the LPA-KIV9 epitope on apo(a). Lp(a) and array of recombinant apo(a) constructs were used to test LPA-KIV9 binding by dot-blot (25 ng protein/dot) (A) and Western blot (B) under reducing conditions (250 ng protein per well). LPA-KIV9 demonstrated a lack of reactivity with plasminogen or KIV2, and high immunoreactivity with Lp(a) and all apo(a) constructs containing KIV9.
Fig. 4. LPA-KIV9 epitope mapping using a printed peptide microarray. A: One hundred overlapping 15-amino acid peptides differing by only one amino acid residue were synthesized on a membrane. B: LPA-KIV9 binding to peptides: LPA-KIV9 binding to peptide array was tested using biotin-anti-mouse-IgG antibody. C: LPA-KIV9 binds to peptides 29-37, which have sequence LETPTVV in common. D: Epitope modeling. The three-dimensional structure of the LPA-KIV9 epitope was predicted by the Swiss-model server. The alignment template SMTL ID was 4dur.2.A plasminogen, with 57.55% sequence identity. The alignment modeling sequence of apo(a) was from Q1386 to C1680. It is predicted that the whole sequence of epitope 4076LETPTVV4082 is a surface loop epitope.
Conflict of interest

A.G., S.T., and J.L.W. are co-inventors and receive royalties from patents owned by the University of California San Diego on oxidation-specific antibodies and of biomarkers related to oxidized lipoproteins. S.T. and J.L.W. are co-founders and have an equity interest in Oxitope, Inc. and its affiliates (Oxitope) as well as in Kleanthi Diagnostics, LLC (Kleanthi). Although these relationships have been identified for conflict of interest management based on the overall scope of the project and its potential benefit to Oxitope and Kleanthi, the research findings included in this particular publication may not necessarily relate to the interests of Oxitope and Kleanthi. The terms of this arrangement have been reviewed and approved by the University of California San Diego in accordance with its conflict of interest management policies. S.T. has a dual appointment at University of California San Diego and Ionis Pharmaceuticals. J.L.W. is a consultant to Ionis Pharmaceuticals. M.L.K. is a paid consultant for Ayma Therapeutics. The other authors declare that they have no conflicts with the contents of this article.

Abbreviations

KIV, kringle IV; KV, kringle V; Lp(a), lipoprotein (a).

References

1. Kronenberg, F., and G. Utermann. 2013. Lipoprotein(a): resurrected by genetics. J. Intern. Med. 273:6–30.
2. Schmidt, K., A. Nourwen, F. Kronenberg, and G. Utermann. 2016. Structure, function, and genetics of lipoprotein(a). J. Lipid Res. 57: 1379–1399.
3. Tsimikas, S., S. Fazio, K. C. Ferdinand, H. N. Ginsberg, M. L. Koschnisky, S. M. Marcovina, P. M. Moriarty, D. J. Rader, A. T. Remaley, G. Reyes-Soffer, et al. 2018. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J. Am. Coll. Cardiol. 71: 177–192.
4. Villaile, P., P. P. R. M. Ridker, P. J. Nestel, J. Simes, A. M. Tomkin, T. R. Pedersen, G. G. Schwartz, A. G. Olsson, H. M. Colhoun, F. Kronenberg, et al. 2018. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Lancet. 392: 1311–1320.
5. Tsimikas, S., E. Karwatowska-Prokopczuk, I. Gouni-Berthold, J. C. Tardif, S. J. Baum, E. Steinhagen-Thiessen, M. D. Shapiro, E. S. Stroes, P. M. Moriarty, B. N. Nordestgaard, et al. 2020. Lipoprotein(a) reduction in persons with cardiovascular disease. N. Engl. J. Med. 382: 244–255.
6. Tsimikas, S., N. J. Viney, S. G. Hughes, W. Singleton, M. J. Graham, B. F. Baker, J. L. Burkey, Q. Yang, S. M. Marcovina, R. S. Gery, et al. 2015. Anti-sense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 386: 1472–1483.
7. Viney, N. J., J. C. van Capelleveen, R. S. Gery, S. Xia, J. A. Tami, R. Z. Yu, S. M. Marcovina, S. G. Hughes, M. J. Graham, R. M. Crooke, et al. 2016. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 388: 2239–2253.
8. Catapano, A. L., I. Gough, G. De Backer, O. Wiklund, M. J. Chapman, H. Dreixel, A. W. Hoes, C. S. Jennings, U. Landmesser, T. R. Pedersen, et al. 2016. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur. Heart J. 37: 2999–3058.
9. Anderson, T. J., J. Gregoire, G. J. Pearson, A. R. Barry, P. Couture, M. Davies, G. A. Francis, J. Genest, Jr., S. Grover, M. Gupta, et al. 2016. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Cans. J. Cardiol. 32: 1263–1282.
10. Stefanutti, C., U. Julius, G. F. Watts, M. Harada-Shiba, M. Cossu, V. J. Schettler, G. De Silvestro, H. Soran, J. R. Van Lenten, L. Pisciotta, et al. 2017. Toward an international consensus-integrating lipoprotein apheresis and new lipid lowering drugs. J. Clin. Lipidol. 11: 858–871.
11. Grundy, S. M., N. J. Stone, A. L. Bailey, C. Beam, K. K. Birtcher, R. S. Blumenthal, L. T. Braun, S. de Ferrari, J. Fiaella-Tommassino, D. E. Forman, et al. 2019. 2018 AHA/ACC/ACCVPR/AAPA/ABC/ACPM/ADA/AGS/AHPA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 73: 3168–3290.
12. Wilson, D. P., T. A. Jacobson, P. H. Jones, M. L. Koschinsky, C. J. McNeal, B. G. Nordestgaard, and G. E. Orringer. 2019. Use of lipoprotein(a) in clinical practice: a biomarker whose time has come: A scientific statement from the National Lipid Association. J. Clin. Lipidol. 13: 374–392.
13. Cegla, J., R. D. G. Neely, M. France, G. Ferns, C. D. Byrne, J. Halcox, D. Datta, N. Capps, C. Shoulders, N. Qureshi, et al. 2019. HEART UK consensus statement on Lipoprotein(a): a call to action. Atherosclerosis. 291: 62–70.
14. Mach, F. C. Baigent, A. L. Catapano, K. C. Koskins, M. Casula, L. Badimon, M. J. Chapman, G. G. De Backer, V. Delgado, B. A. Ference, et al. 2020. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur. Heart J. 41: 111–188.
15. Marcovina, S. M., J. J. Albers, B. Gabel, M. L. Koschinsky, and V. P. Gaur. 1995. Effect of the number of apolipoprotein(a) kringle 4 domains on immunnochemical measurements of lipoprotein(a). Clin. Chem. 41: 246–255.
16. Schneider, M., J. L. Witztum, S. G. Young, E. H. Ludvig, E. R. Miller, S. Tsimikas, L. K. Curtis, S. M. Marcovina, J. M. Taylor, R. M. Law, et al. 2005. High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoprotein. J. Lipid Res. 46: 769–778.
17. van der Valk, F. M., S. Bekkerling, I. Kroon, C. Yeang, J. Van den Bossche, J. D. van Buul, A. Ravandi, A. J. Nederveen, H. J. Verberne, C. Scipione, et al. 2016. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 134: 611–624.
18. Hancock, M. A., M. B. Boffa, S. M. Marcovina, M. E. Neshime, and M. L. Koschinsky. 2003. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J. Biol. Chem. 278: 23260–23269.
19. Leibundgut, G., C. Scipione, H. Yin, M. Schneider, M. B. Boffa, S. Green, X. Yang, E. H. Ludvig, E. R. Miller, J. L. Witztum, et al. 2013. Determinants of binding of oxidized phospholipid on apolipoprotein(a) and lipoprotein (a). J. Lipid Res. 54: 2815–2830.
20. Cheesman, E. J., R. J. Sharp, C. H. Zlot, C. Y. Liu, S. Taylor, S. M. Marcovina, S. G. Young, and S. P. McCormick. 2000. An analysis of the interaction between mouse apolipoprotein B100 and apolipoprotein(a). J. Biol. Chem. 275: 28195–28200.
21. Young, S. G., R. S. Smith, D. M. Hoge, L. K. Curtiss, and J. L. Witztum. 1986. Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B 100 and apolipoprotein(a). J. Biol. Chem. 261: 29105–29109.
22. Weisgraber, K. H., T. L. Innerarity, G. S. Gaur, M. K. E. Niehues, K. S. Arnold, R. M. Krauss, G. L. Vega, S. M. Grundy, and R. W. Mahley. 1991. Familial defective apolipoprotein B-100 elicits arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 104: 390–397.
associated with apoAI and apoB-100 lipoproteins in human plasma. 
*J. Lipid Res.* **60**: 436–445.

26. Gabel, B. R., L. F. May, S. M. Marcovina, and M. L. Koschinsky. 1996. Lipoprotein(a) assembly: Quantitative assessment of the role of apo(a) kringle IV types 2–10 in particle formation. *Arterioscler. Thromb. Vasc. Biol.* **16**: 1559–1567.

27. Biasini, M., S. Bienert, A. Waterhouse, K. Arnold, G. Studer, T. Schmidt, F. Kiefer, T. Gallo Cassarino, M. Bertoni, L. Bordoli, et al. 2014. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. *Nucleic Acids Res.* **42**: W252–W258.

28. Scharnagl, H., T. Stojakovic, B. Dieplinger, H. Dieplinger, G. Erhart, G. M. Kostner, M. Herrmann, W. Marz, and T. B. Grammer. 2019. Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays. *Atherosclerosis.* **289**: 206–213.

29. Marcovina, S. M., and J. J. Albers. 2016. Lipoprotein (a) measurements for clinical application. *J. Lipid Res.* **57**: 526–537.

30. McLean, J. W., J. E. Tomlinson, W. J. Kuang, D. L. Eaton, E. Y. Chen, G. M. Fless, A. M. Scanu, and R. M. Lawn. 1987. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. *Nature.* **330**: 132–137.